Press releaseBusiness Wire
Bayer AG
BAYZF · XETRA
$49.38+$0.58 (+1.19%)TodayMarket closed ·
No price history for this range.
Latest news
- Press releaseBusiness Wire
Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet® (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause
- Press releaseBusiness Wire
U.S. FDA Accepts Bayer’s Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes
- Press releaseBusiness Wire
Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States
- Press releaseBusiness Wire
Alka-Seltzer Plus® to Relaunch as Alka-Seltzer™ Cold in 2026, Bringing Simpler Shopping and More Value to the Cough/Cold Aisle
- Press releaseBusiness Wire
MiraSOFT™ Launch at CVS Pharmacy, Expanding the MIRA Portfolio with a Stool Softener Option
- Press releaseBusiness Wire
U.S. FDA Accepts sNDA and Grants Priority Review to Bayer’s Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer
- Press releaseBusiness Wire
Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs
- Press releaseBusiness Wire
Bayer’s KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
- Press releaseBusiness Wire
Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road
- Press releaseBusiness Wire
U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer
- Press releaseBusiness Wire
BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATION
- Press releaseBusiness Wire
Bayer Announces Phase III REVEAL Study with Investigational PET Radiotracer Iodine 124 Evuzamitide Presented as Late-Breaker at ESC 2026
- Press releaseBusiness Wire
Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026
- Press releaseBusiness Wire
LYNKUET® (elinzanetant) Receives Expanded Market Authorization in Canada for Treatment of Moderate to Severe Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy (AET) Related to Breast Cancer
- Press releaseBusiness Wire
One A Day® Introduces New Women's Multi Gummy Formula with 1,000 mcg Biotin
- Press releaseBusiness Wire
New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters
- Press releaseBusiness Wire
Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials
- Press releaseBusiness Wire
The University of Colorado Anschutz, along with UCHealth and Children’s Hospital Colorado, Form Strategic Alliance with Bayer to Advance Drug Development and Clinical Trials
- Press releaseBusiness Wire
Luke Bryan and One A Day® Launch Limited Edition Multivitamin Bottles Available Only at Walmart
- Press releaseBusiness Wire
Bayer Group to Consolidate U.S. Glyphosate Business Into Distinct Entity Operating as Ruveon
- Press releaseBusiness Wire
Bayer and Iambic Collaborate to Advance Drug Discovery with AI
- Press releaseBusiness Wire
Bayer Welcomes Kacy Perry as New Country Division Head for Crop Science Canada
- Press releaseBusiness Wire
Bayer Completes Acquisition of Perfuse Therapeutics
- Press releaseBusiness Wire
Aleve® Launches its Project DIY Campaign with HGTV Stars Dave & Jenny Marrs to Highlight Hardworking Hobbyists and Long-Lasting Pain Relief
- Press releaseBusiness Wire
Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack
- Press releaseBusiness Wire
U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer
- Press releaseBusiness Wire
Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis
- Press releaseBusiness Wire
Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline
- Press releaseBusiness Wire
Bayer Accelerates Pharma Growth on High-Value Portfolio
- Press releaseBusiness Wire
Actress and Menopause Advocate Gabrielle Union-Wade Partners with Bayer in the Lynkuet® (elinzanetant) 'Life Doesn't Stop for a Hot Flash' Campaign for Moderate to Severe Hot Flashes Due to Menopause
- Press releaseBusiness Wire
RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints
- Press releaseBusiness Wire
U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- NewsVandana Singh
Agricultural Conglomerate Bayer Confident In Long-Term Outlook Despite Litigation Risks
- News
Bayer Confirms Its 2024 Guidance, Sales Of €47B-€49B And Core Earnings Per Share Of €5.10-€5.50
- NewsVandana Singh
Bayer Weedkiller Lawsuit Dismissed By Australian Judge: Insufficient Evidence Linking Roundup To Blood Cancer
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.